Can a smartphone app help melanoma patients avoid severe side effects from immunotherapy?

NCT ID NCT07660666

First seen Jun 27, 2026 ยท Last updated Jun 27, 2026

Summary

This study tests whether having melanoma patients regularly report their symptoms through an electronic tool, combined with quick access to specialist care, can improve the management of side effects from immune checkpoint inhibitors. These drugs can cause immune-related side effects that range from mild to life-threatening. The trial enrolls 50 patients starting standard immunotherapy, along with their caregivers, to see if this monitoring approach is feasible and helps catch problems early.

What this could mean

Our plain-language read of the trial. This is informational only โ€” not medical advice or a prediction.

Active substance
electronic patient-reported outcomes tool and patient navigation
What this could lead to
If successful, this approach could help doctors catch and treat immunotherapy side effects earlier, potentially reducing severe complications and treatment interruptions.
What could go wrong
This is a small feasibility study (50 participants) focused on whether the process works, not yet on proving it improves outcomes. Results may not apply to all melanoma patients or other cancers.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MELANOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • OHSU Knight Cancer Institute

    Portland, Oregon, 97239, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.